THX Pharma Société Anonyme (ALTHX) Stock Overview
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ALTHX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
THX Pharma Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.48 |
| 52 Week High | €5.10 |
| 52 Week Low | €1.49 |
| Beta | 1.51 |
| 1 Month Change | -24.02% |
| 3 Month Change | 9.61% |
| 1 Year Change | 30.83% |
| 3 Year Change | 188.56% |
| 5 Year Change | -58.32% |
| Change since IPO | -78.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALTHX | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -15.7% | -3.1% | -0.4% |
| 1Y | 30.8% | -3.8% | 2.0% |
Return vs Industry: ALTHX exceeded the French Pharmaceuticals industry which returned -3.8% over the past year.
Return vs Market: ALTHX exceeded the French Market which returned 2% over the past year.
Price Volatility
| ALTHX volatility | |
|---|---|
| ALTHX Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALTHX's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALTHX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 12 | Mathieu Charvériat | www.theranexus.com |
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025.
THX Pharma Société Anonyme Fundamentals Summary
| ALTHX fundamental statistics | |
|---|---|
| Market cap | €48.01m |
| Earnings (TTM) | -€3.00m |
| Revenue (TTM) | €806.05k |
Is ALTHX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTHX income statement (TTM) | |
|---|---|
| Revenue | €806.05k |
| Cost of Revenue | €2.23m |
| Gross Profit | -€1.43m |
| Other Expenses | €1.57m |
| Earnings | -€3.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 29, 2026
| Earnings per share (EPS) | -0.22 |
| Gross Margin | -177.00% |
| Net Profit Margin | -372.38% |
| Debt/Equity Ratio | 99.3% |
How did ALTHX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 01:06 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
THX Pharma Société Anonyme is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mohamed Kaabouni | Portzamparc BNP Paribas |
| Victor Floch | Stifel, formerly Bryan Garnier |